Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) hope to expand Libtayo into a broader population with a chemo combo regimen.
- According to data released at the European Society for Medical Oncology 2021 (ESMO21), Libtayo, used on top of platinum doublet chemotherapy, reduced the risk of death by 29% over chemo alone in patients with previously untreated, advanced non-small cell lung cancer (NSCLC).
- The phase 3 Empower-Lung 3 trial included both squamous and nonsquamous NSCLC patients.
- Libtayo-chemo hit a median overall survival (OS) of 22 months versus 13 months for the solo chemo group, with a median progression-free survival of 8 months.
- The Libtayo combo posted a 43% response rate compared with 23% for chemo and a 16-month duration response versus 7 months for chemo. No new Libtayo safety signals were identified.
- Exploratory analyses showed survival improvements across squamous and nonsquamous histologies and in patients with reduced daily functioning.
- In another exploratory analysis, the Libtayo combination helped delay patient-reported quality of life deterioration and pain symptoms.
- Price Action: REGN stock closed 0.20% lower at $651.88, and SNY stock closed at 0.39% higher at $48.38 on Friday.
- Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!